Breadcrumb AMCP.org Policy & Advocacy Letters, Statements & Analysis AMCP Delivers Remarks on Biosimilars Position at FDA Oncologic Drug Advisory Committee Meeting AMCP Delivers Remarks on Biosimilars Position at FDA Oncologic Drug Advisory Committee Meeting 5/25/17 Tweet this pagePost this page on FacebookPost this page on LinkedInEmail this pagePrint this page AMCPRemarks_FDAAdComMeeting_OncologicDRugs_May2017.pdf Tweet this pagePost this page on FacebookPost this page on LinkedInEmail this pagePrint this page